VITAMIN E SUPPLEMENT BLOCKS THE RESPONSE OF HDL TO LOVASTATIN THERAPY IN HYPERCHOLESTROLEMIC PATIENTS

HDL can prevent LDL-c oxidation. The low HDL-c State also may benefit clinically from supplemented antioxidant. This study was designed to evaluate the combination therapy of statin and vitamin E in hypercholesterolemic patients. The patients were randomized in a clinical trial aimed to avaluate th...

Full description

Bibliographic Details
Main Authors: S. M. Namayandeh, M. Emami-Meybody, S. M. Sadr Bafghi, S. Yeganehfard, M. Kamran M. Motafaker
Format: Article
Language:English
Published: Tehran University of Medical Sciences 2007-08-01
Series:Acta Medica Iranica
Subjects:
Online Access:https://acta.tums.ac.ir/index.php/acta/article/view/3285
id doaj-fb50da7c3ee64c09ae455fee280010ad
record_format Article
spelling doaj-fb50da7c3ee64c09ae455fee280010ad2020-11-25T03:33:12ZengTehran University of Medical SciencesActa Medica Iranica0044-60251735-96942007-08-01454VITAMIN E SUPPLEMENT BLOCKS THE RESPONSE OF HDL TO LOVASTATIN THERAPY IN HYPERCHOLESTROLEMIC PATIENTS S. M. Namayandeh0 M. Emami-Meybody1 S. M. Sadr Bafghi2 S. Yeganehfard3 M. Kamran M. Motafaker4 HDL can prevent LDL-c oxidation. The low HDL-c State also may benefit clinically from supplemented antioxidant. This study was designed to evaluate the combination therapy of statin and vitamin E in hypercholesterolemic patients. The patients were randomized in a clinical trial aimed to avaluate the effect of vitamin E and/or statin.The life style of patients didn't alter during intervention. The subjects were randomized to two treatment groups A and B: (1) lovastatin 20mg daily at bedtime. (group A); (2) vitamin E 400 iu daily plus lovastatin 20 mg daily (group B). The lipid values of each patients at baseline and after 8 weeks of treatment were compared by paired t test. The mean baseline lipid levels for 60 subjects were as follows: plasma cholesterol, triglyceride, LDL-c and HDL-c 285 ± 68, 268 ± 121, 158 ± 32, 49 ± 11 mg/dl respectively. Serum lipid levels changes in group A (statin only) and in group B (statin and vitamin E) were statistically significant. In comparison of lipid profiles changes between two groups we observed that HDL-c changes in group B were significantly lower than in group A. Vitamin E supplement blocks the respons of HDL-c to lovastatin therapy in hypercholestrolemic patients. https://acta.tums.ac.ir/index.php/acta/article/view/3285HDL-Cholestrol
collection DOAJ
language English
format Article
sources DOAJ
author S. M. Namayandeh
M. Emami-Meybody
S. M. Sadr Bafghi
S. Yeganehfard
M. Kamran M. Motafaker
spellingShingle S. M. Namayandeh
M. Emami-Meybody
S. M. Sadr Bafghi
S. Yeganehfard
M. Kamran M. Motafaker
VITAMIN E SUPPLEMENT BLOCKS THE RESPONSE OF HDL TO LOVASTATIN THERAPY IN HYPERCHOLESTROLEMIC PATIENTS
Acta Medica Iranica
HDL-Cholestrol
author_facet S. M. Namayandeh
M. Emami-Meybody
S. M. Sadr Bafghi
S. Yeganehfard
M. Kamran M. Motafaker
author_sort S. M. Namayandeh
title VITAMIN E SUPPLEMENT BLOCKS THE RESPONSE OF HDL TO LOVASTATIN THERAPY IN HYPERCHOLESTROLEMIC PATIENTS
title_short VITAMIN E SUPPLEMENT BLOCKS THE RESPONSE OF HDL TO LOVASTATIN THERAPY IN HYPERCHOLESTROLEMIC PATIENTS
title_full VITAMIN E SUPPLEMENT BLOCKS THE RESPONSE OF HDL TO LOVASTATIN THERAPY IN HYPERCHOLESTROLEMIC PATIENTS
title_fullStr VITAMIN E SUPPLEMENT BLOCKS THE RESPONSE OF HDL TO LOVASTATIN THERAPY IN HYPERCHOLESTROLEMIC PATIENTS
title_full_unstemmed VITAMIN E SUPPLEMENT BLOCKS THE RESPONSE OF HDL TO LOVASTATIN THERAPY IN HYPERCHOLESTROLEMIC PATIENTS
title_sort vitamin e supplement blocks the response of hdl to lovastatin therapy in hypercholestrolemic patients
publisher Tehran University of Medical Sciences
series Acta Medica Iranica
issn 0044-6025
1735-9694
publishDate 2007-08-01
description HDL can prevent LDL-c oxidation. The low HDL-c State also may benefit clinically from supplemented antioxidant. This study was designed to evaluate the combination therapy of statin and vitamin E in hypercholesterolemic patients. The patients were randomized in a clinical trial aimed to avaluate the effect of vitamin E and/or statin.The life style of patients didn't alter during intervention. The subjects were randomized to two treatment groups A and B: (1) lovastatin 20mg daily at bedtime. (group A); (2) vitamin E 400 iu daily plus lovastatin 20 mg daily (group B). The lipid values of each patients at baseline and after 8 weeks of treatment were compared by paired t test. The mean baseline lipid levels for 60 subjects were as follows: plasma cholesterol, triglyceride, LDL-c and HDL-c 285 ± 68, 268 ± 121, 158 ± 32, 49 ± 11 mg/dl respectively. Serum lipid levels changes in group A (statin only) and in group B (statin and vitamin E) were statistically significant. In comparison of lipid profiles changes between two groups we observed that HDL-c changes in group B were significantly lower than in group A. Vitamin E supplement blocks the respons of HDL-c to lovastatin therapy in hypercholestrolemic patients.
topic HDL-Cholestrol
url https://acta.tums.ac.ir/index.php/acta/article/view/3285
work_keys_str_mv AT smnamayandeh vitaminesupplementblockstheresponseofhdltolovastatintherapyinhypercholestrolemicpatients
AT memamimeybody vitaminesupplementblockstheresponseofhdltolovastatintherapyinhypercholestrolemicpatients
AT smsadrbafghi vitaminesupplementblockstheresponseofhdltolovastatintherapyinhypercholestrolemicpatients
AT syeganehfard vitaminesupplementblockstheresponseofhdltolovastatintherapyinhypercholestrolemicpatients
AT mkamranmmotafaker vitaminesupplementblockstheresponseofhdltolovastatintherapyinhypercholestrolemicpatients
_version_ 1724564128964542464